We are excited to announce that KiraGen Bio has been selected as a Boston Regional Finalist in the Harvard Business School (HBS) New Venture Competition – Alumni Track! This milestone puts us one step closer to the Global Finals, where the winning team will receive a $75,000 grand prize.
A Testament to Innovation and Impact
The HBS New Venture Competition is a prestigious platform that brings together top ventures from around the world, recognizing startups that demonstrate transformative potential. Making it to the Boston Regional Finals is a significant validation of our mission to engineer multiplex-edited cell therapies that conquer the tumor microenvironment (TME) and transform the treatment of solid tumors.
KiraGen Bio is at the forefront of next-generation cell therapy innovation, leveraging AI-driven gene editing strategiesto enhance CAR-T cell persistence and efficacy in solid tumors. Our lead program in glioblastoma (GBM) builds upon the foundation set by leading academic institutions and represents a meaningful step toward improving treatment outcomes for patients with some of the most challenging cancers.
What’s Next?
As we prepare to compete in the Boston Regional Finals, we are eager to share our vision with a distinguished panel of judges, investors, and industry leaders. The Regional winners will advance to the Global Finals, where they will compete for the top prize and global recognition among HBS alumni-founded startups.
This achievement is a reflection of the dedication and hard work of our team, as well as the incredible support from our advisors, collaborators, and community. We look forward to representing KiraGen Bio in this competition and continuing our mission to push the boundaries of solid tumor cell therapy innovation.
Stay tuned for updates as we move forward in the competition!